Tumor-Targeting Nanotechnology Platform with Enhanced Drug Delivery Capabilities

SK1363 and SK2016-113

Tumor-Targeting Nanotechnology Platform with Enhanced Drug Delivery Capabilities

SK1363 and SK2016-113


While nanoparticles are widely used as drug delivery vehicles, the release of drugs specifically at disease sites remains a challenge.  Liposomal nanoparticles carrying drug payloads can accumulate near tumors because of the enhanced permeation and retention (EPR) effect.  While this increases the amount of nanoparticles at the tumor site, drugs can become trapped inside the liposomal envelope of the nanoparticle, remaining blocked from accessing the site of disease.  

MSK investigators have developed specialized nanoparticles with efficient and controlled drug release at tumor sites.  The liposomes of the nanoparticle contain the lipid sphingomyelin. Sphingomyelin is converted to the lipid ceramide by the enzyme sphingomyelinase, which is spontaneously generated by tumors, and activated by radiation and chemotherapy.  Therefore, sphingomyelin in the lipid bilayer of liposomal nanoparticles at tumor sites is converted to ceramide, the presence of which leads to liposomal rupture and release of the drug payload.  These proprietary nanoparticles also include a magnetic particle to enhance liposomal rupture, allowing for stronger and more selective drug release.  

These sphingomyelin-containing nanoparticles can be used clinically to carry and deliver any small molecule drug or chemotherapeutic agent to tumor sites for therapeutic purposes.  They can also be loaded with radiological contrast agents to monitor and thereby enhance therapeutic response to radiation therapy.    


  • Proprietary nanotechnology platform includes two sets of IP that can be jointly licensed to achieve maximum potential
  • Allows for targeted drug delivery and release specifically at tumor sites, with the potential to reduce side effects due to systemic drug delivery
  • Could be used to deliver any small molecule drug or chemotherapeutic for therapeutic purposes as well as PET imaging agents for radiology
  • In vivo proof-of-concept demonstrated in a mouse model of squamous cell carcinoma, with decreased tumor growth and increased survival of mice treated with cisplatin-encapsulated nanoparticles compared to cisplatin alone


This nanotechnology platform is a safe and efficient tool to deliver small molecule drugs and chemotherapies to tumors.




  • SK2016-113: U.S. National Application 15/308,770 published January 2017; Europe National application published
  • SK1363:  U.S. Basic application 14/162,494 published July 2014; Europe National 3139964 granted April 2019; Nationals issued in France, Germany, U.K., Italy, and Spain.


Jan Grimm, PhD, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, MSK

Oula Peñate Medina, PhD, Former MSK


James Delorme, PhD

Licensing Manager
Tel: 332-229-0588
E-mail: [email protected]

Stage of Development

Animal studies